Zomedica (NYSEAMERICAN:ZOM – Get Rating) posted its quarterly earnings data on Wednesday. The company reported ($0.01) EPS for the quarter, Yahoo Finance reports. Zomedica had a negative return on equity of 6.51% and a negative net margin of 104.92%. The firm had revenue of $6.16 million for the quarter, compared to analysts’ expectations of $6.20 million.
Zomedica Stock Down 1.5 %
Shares of NYSEAMERICAN ZOM opened at $0.23 on Friday. Zomedica has a 1 year low of $0.15 and a 1 year high of $0.41.
Wall Street Analyst Weigh In
Separately, Dawson James assumed coverage on Zomedica in a report on Friday, January 6th. They issued a “buy” rating and a $6.00 price target for the company.
Institutional Inflows and Outflows
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.
- Get a free copy of the StockNews.com research report on Zomedica (ZOM)
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
- PacWest Bancorp May Escape a Credit Downgrade After this Happens
- Dollar General Offers Great Prices, but the Stock isn’t a Value
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.